Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer
Ontology highlight
ABSTRACT: This trial is being performed in two parts: Dose Escalation and Dose Expansion.
The primary objective for the Dose Escalation part is to determine the safety and tolerability at different doses of DS-8273a administered in combination with nivolumab and to identify the dose combination for the Dose Expansion cohort in subjects with mismatch repair (MMR)-proficient advanced colorectal cancer.
The primary objectives for the Dose Expansion part are:
* To further evaluate the safety and tolerability of DS-8273a administered at the selected dose in combination with nivolumab in subjects with MMR-proficient advanced colorectal cancer
* To evaluate preliminary anti-tumor activity of DS-8273a plus nivolumab administered at the selected dose in subjects with MMR-proficient advanced colorectal cancer
DISEASE(S): Colorectal Neoplasm,Colorectal Neoplasms
PROVIDER: 2231940 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA